Global Radiolabelled ADME Studies Market Growth (Status and Outlook) 2024-2030

Global Radiolabelled ADME Studies Market Growth (Status and Outlook) 2024-2030

Radiolabelled ADME studies utilize radiolabelled (radioactive) versions of a drug to track its journey through the body. The radioactive label allows for precise detection and quantification of the drug and its metabolites, facilitating a comprehensive understanding of its pharmacokinetic profile.

The global Radiolabelled ADME Studies market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Radiolabelled ADME Studies Industry Forecast” looks at past sales and reviews total world Radiolabelled ADME Studies sales in 2022, providing a comprehensive analysis by region and market sector of projected Radiolabelled ADME Studies sales for 2023 through 2029. With Radiolabelled ADME Studies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radiolabelled ADME Studies industry.

This Insight Report provides a comprehensive analysis of the global Radiolabelled ADME Studies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radiolabelled ADME Studies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radiolabelled ADME Studies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radiolabelled ADME Studies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radiolabelled ADME Studies.

United States market for Radiolabelled ADME Studies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Radiolabelled ADME Studies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Radiolabelled ADME Studies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Radiolabelled ADME Studies players cover Charles River, Eurofins Scientific, Evotec, Labcorp, Sekisui Medical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Radiolabelled ADME Studies market by product type, application, key players and key regions and countries.

Segmentation by Type:
C-14
H-3
Others

Segmentation by Application:
Biopharmaceutical Companies
Government and Academic Institutes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
C-14
H-3
Others

Segmentation by Application:
Biopharmaceutical Companies
Government and Academic Institutes
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Charles River
Eurofins Scientific
Evotec
Labcorp
Sekisui Medical
XenoTech (BioIVT)
QPS
BioDuro-Sundia
Quotient Sciences
Chelatec
HMR
Nuvisan
Fluorizon
WuXi AppTec
Pharmaron
InnoStar
Medicilon
Frontage
Value Pharmaceutical
New Radiomedicine Technology

Please note: The report will take approximately 2 business days to prepare and deliver.